Skip to main content
CYTK logo

Cytokinetics, Incorporated (CYTK) Stock: Price, Forecast & Analyst Target

Cytokinetics, Incorporated (CYTK) — MoonshotScore 12/100 (Weak band), calculated Nov 18, 2026. Price $51.46 (+0.27%), as of the Nov 19, 2026 trading session; market cap $7.17B. Expected results Feb 23, 2027.

Educational signal · not a buy or sell recommendation · How to read this

Market value / cash and short-term investments: 6.35× (cash as of Sep 30, 2026) · expected results Feb 23, 2027

$51.46 +$0.14 (+0.27%) Market Cap $7.17B

Cytokinetics, Incorporated · CYTK · NASDAQ · Healthcare · Biotechnology

Research dated 2026-09-13: Cytokinetics develops medicines that alter muscle contractility and now markets MYQORZO, an oral cardiac myosin inhibitor for symptomatic obstructive hypertrophic cardiomyopathy. Its valuation hinges on whether MYQORZO demand and international aficamten launches can outrun a heavy research and commercial cost base before ongoing cash use narrows its financial flexibility.

Price as of Nov 19, 2026

Key Statistics

12 of 100

MoonshotScore v2 · Cytokinetics (CYTK)

Weak
Business Quality Thin (27)
Financial Safety Strained (38)
Valuation Full (44)
Growth Durability Fading (27)
Momentum Quiet (44)
Why this rating? Method, drivers & history

Bands for the MoonshotScore: Exceptional 80-100 · Strong 65-79 · Fair 45-64 · Weak below 45.

  • Business Quality — Is this a genuinely good business?
  • Financial Safety — Could this blow up on me?
  • Valuation — Am I paying a fair price?
  • Growth Durability — Is the growth real and likely to last?
  • Momentum — Is the market already moving on this?
The ten-second read ·

Weak quality, a strained balance sheet, weak growth and a full valuation. The score also carries a risk penalty for a bankruptcy-risk score in the distress zone and losses on top of negative retained earnings. Business Quality: Thin; Financial Safety: Strained; Valuation: Full; Growth Durability: Fading; Momentum: Quiet.

  • EPS beat 5 of the last 8 reports
  • Altman Z -1.79 · Piotroski F 2

Holding back: weak fundamentals, soft growth

What has the MoonshotScore done over time?

MoonshotScore snapshots recorded for CYTK (57 recorded, newest six shown)
RecordedScoreBand
12Weak
12Weak
12Weak
12Weak
12Weak
12Weak

Daily score refresh is delayed. This is the last recorded calculation.

Calculation uses the most recent completed US trading session. Live price changes do not update the score immediately.

Computed · How the MoonshotScore is computed →

Price & valuation

Dates shown where recorded
MeasureValueAs of
Latest provided price$51.46
Change on the day+0.27%
52-week range$51.38–$88.31
Market capitalisation$7.17B—
Price / earnings (trailing)-17.39
Shares traded on the day1.74M
Beta (volatility vs the S&P 500)0.36

Price & events

Weekly closing price with reported quarters marked Weekly closing price from Oct 17, 2025 to Nov 19, 2026: low $51, high $86, latest $51. 4 reported quarters marked, 2 above and 1 below the recorded estimate. 1 other dated event marked. $86 $51 high $86 Feb 24, 2026 · Earnings results · reported below the recorded estimate · close $621May 5, 2026 · Earnings results · reported in line with the recorded estimate · close $772Aug 6, 2026 · Earnings results · reported above the recorded estimate · close $773Nov 4, 2026 · Earnings call · management outlook · no recorded estimate to compare · close $544Nov 4, 2026 · Earnings results · reported above the recorded estimate · close $545 Oct 17, 2025 Nov 19, 2026 · $51 $58Oct 17, 2025$64Oct 31, 2025$66Nov 14, 2025$68Nov 28, 2025$63Dec 12, 2025$63Dec 26, 2025$63Jan 9, 2026$63Jan 23, 2026$62Feb 6, 2026$68Feb 20, 2026$60Mar 6, 2026$62Mar 20, 2026$67Apr 2, 2026$67Apr 17, 2026$63May 1, 2026$76May 15, 2026$77May 29, 2026$70Jun 12, 2026$82Jun 26, 2026$85Jul 10, 2026$81Jul 24, 2026$77Aug 7, 2026$77Aug 21, 2026$73Sep 4, 2026$69Sep 18, 2026$66Oct 2, 2026$62Oct 16, 2026$63Oct 30, 2026$56Nov 13, 2026

Triangles mark reported quarters on the line: pointing up is above the recorded estimate, down is below, a diamond means no estimate on file or a dated event that is not a results report. Numbers key to the dated list. Point at or tab to any week for its close.

Events behind the price

  • · Earnings results · below the recorded estimate
  • · Earnings results · in line with the recorded estimate
  • · Earnings results · above the recorded estimate
  • · Earnings call · management outlook
  • · Earnings results · above the recorded estimate

Results dates follow the earnings feed; call dates follow the transcript provider. Nearby dates do not establish that an event caused a price move.

Upcoming events

As of

  1. Next results dueProvider estimate

Management outlook

  • We expect to launch in the U.K. this quarter and in additional countries in 2027.

    Robert I. Blum · Statement from

  • We also recently received approval in Canada, and we expect to launch in the U.K. this quarter and in additional countries in 2027.

    Andrew Callos · Statement from

How to read these dates

A statement's date is the earnings call where it was made, not a deadline. Management expectations and estimated dates can change.

Read management statements

Other perspectives

Council score for Cytokinetics (CYTK): perspectives

Some lenses disagree with the MoonshotScore. Compare their readings below; each uses a different method.

5-Factor Breakdown

Business Quality Weak
Financial Safety Weak
Valuation Neutral
Growth Durability Weak
Momentum Neutral

Legends Council

5 lenses, 5 current

AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built

Dalio-style lens (simulated) Ray Dalio Favorable read
Griffin-style lens (simulated) Ken Griffin Unfavorable read
Englander-style lens (simulated) Izzy Englander Favorable read
Klarman-style lens (simulated) Seth Klarman Neutral read
Moon AI lens (model) Neutral read

Read on: Nov 20, 2026

Munger's Mindset

Balance Sheet & Valuation · historical

Financial Health Neutral
Margin of Safety Fairly Valued
Profit Margin Weak
Revenue Growth Strong
Gross Margin Negative

Read on: Nov 18, 2026 · older than the 27 hours refresh window; not a current reading

How to read these bars and different assessments

Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.

Bars show each model's ordered assessment on its own scale, not a probability or a comparable investment return. The adjacent words give the assessment; more filled segments indicate a stronger model reading.

Two of these lenses read this company more favourably than the MoonshotScore does: Dalio-style lens and Englander-style lens. Each lens is a separate scoring function over its own inputs, so a disagreement is a difference of method rather than a correction — the page's answer stays the MoonshotScore above.

On Nov 18, 2026, the Munger lens read the price at that time as fairly valued against its own estimate of value.

Readings on this page are from Nov 20, 2026, except a card that shows its own read date.

1 · What is it?

What is Cytokinetics (CYTK), and what does it report?

Short answer · as of

Cytokinetics sells and develops muscle activators and inhibitors, with demand ultimately tied to treatment adoption among eligible cardiac and skeletal-muscle patients.

MYQORZO provides a marketed product, while aficamten, omecamtiv mecarbil, Ulacamten and the skeletal-muscle program extend the same contractility-focused research platform across different diseases.

Reported revenue is not yet a clean proxy for MYQORZO prescription demand. The annual segment disclosure identifies collaboration revenue, quarterly revenue has swung sharply, and the income statement still reflects a research-intensive company carrying a substantial commercial cost base.

2 · Latest results

What do the latest results show for Cytokinetics (CYTK)?

Revenue and gross profit rose from the preceding period, while operating and net losses narrowed. Reported earnings history also shows revenue ahead of consensus and a less negative loss per share than expected, but operating cash use deepened and selling and administrative expense remained above research spending.

Collaboration economics can make quarterly revenue uneven, so the latest increase does not by itself establish a stable MYQORZO demand curve. Management is directing attention toward the United Kingdom launch and a country-by-country aficamten rollout governed by local health-technology assessment processes.

Where is operating spending going?

Revenue alongside research and development, selling, general and administrative expenses, and the FMP standardized operating result.

Latest quarter · revenue
$47.56M Sep 30, 2026
Latest quarter · R&D
$99.28M Sep 30, 2026
Latest quarter · SG&A
$113.14M Sep 30, 2026
Latest quarter · FMP standardized operating result
−$167.09M Sep 30, 2026
Period endRevenueR&DSG&AFMP standardized operating result
Sep 30, 2026$47.56M$99.28M$113.14M−$167.09M
Jun 30, 2026$28.62M$97.81M$104.40M−$179.17M
Mar 31, 2026$19.36M$95.53M$104.90M−$183.62M
Dec 31, 2025$17.75M$101.54M$91.72M−$178.37M
How to read these figures

Amounts are in US dollars. The operating result is Financial Modeling Prep’s standardized figure, so it can differ from the operating line in the company’s filing. It is not net income or cash flow.

Did results meet expectations?

Reported earnings and revenue alongside the estimates recorded by the provider.

Latest report · revenue
$47.56M Nov 4, 2026
Latest report · revenue estimate
$41.88M Nov 4, 2026
Latest report · revenue vs estimate
Above estimate Nov 4, 2026
Latest report · EPS vs estimate
Above estimate Nov 4, 2026
Report dateRevenue · reportedRevenue · estimateEPS · reportedEPS · estimate
Nov 4, 2026$47.56M$41.88M−$1.3700−$1.4300
Aug 6, 2026$28.62M$17.59M−$1.5000−$1.6300
May 5, 2026$19.36M$8.52M−$1.6700−$1.6700
Feb 24, 2026$17.75M$6.93M−$1.5000−$1.4800
How to read these figures

Dates are when results were reported, not quarter ends. Amounts are in US dollars; EPS is per share. The source does not say whether EPS is basic, diluted or adjusted, so it can differ from the EPS in the income statement.

Quarterly income statement — 4 quarters
Revenue, net income and earnings per share by quarter
PeriodRevenueNet incomeEPS
Sep 2025$2M-$306M-$2.55 (diluted)
Q4 FY2025$18M-$183M-$1.50 (diluted)
Q1 FY2026$19M-$206M-$1.67 (diluted)
Q2 FY2026$29M-$199M-$1.50 (diluted)
3 · Financial strengths and risks

What are the financial strengths and risks for Cytokinetics (CYTK)?

Short answer

Cash and short-term investments were $1.13B at the Sep 30, 2026 balance-sheet date. Operating cash flow was −$124.02M for the quarter ended Sep 30, 2026, meaning operations used cash. These figures do not establish a cash runway.

Cash and short-term investments rose sharply in the latest period, and adding long-term investments puts total liquidity above debt. Cash and short-term investments alone remain below debt, however, while operations continue to consume cash and the computed runway is finite.

The specific financial risk is a slow commercial ramp meeting persistent research and selling costs. Consensus still anticipates losses before profitability emerges, trailing margins remain deeply negative, and the distress and quality screens are weak; continued revenue volatility or heavier launch spending would accelerate pressure on liquidity.

Data-derived red flags

  • Financial-distress signal — its Altman Z-Score of -1.79 sits in the distress zone (elevated bankruptcy risk).
  • Weak fundamentals — a Piotroski F-Score of 2/9 flags soft profitability, leverage or efficiency.

How much cash does the business generate or use?

Quarterly operating cash flow shows cash generated or used by operations.

Latest quarter · operating cash flow
−$124.02M Sep 30, 2026
Previous quarter · operating cash flow
−$159.84M Jun 30, 2026
Period endOperating cash flowCapital expenditure (reported)
Sep 30, 2026−$124.02M−$700,000
Jun 30, 2026−$159.84M−$4.33M
Mar 31, 2026−$145.46M−$5.93M
Dec 31, 2025−$142.65M−$5.64M
How to read these figures

Amounts are in US dollars. Negative operating cash flow means the business used cash. Capital spending is shown as reported; we do not combine it into a free-cash-flow or runway estimate. The bars share one scale.

4 · What to check next?

What should you watch next at Cytokinetics (CYTK)?

Short answer · as of

The next earnings report is expected on Feb 23, 2027.

At the scheduled earnings update, watch whether revenue keeps advancing without another collaboration-driven reversal, whether gross profit remains positive, and whether operating losses and cash use begin to moderate. Commercial leverage would appear as revenue growing faster than selling and administrative expense rather than spending merely shifting from research toward launch activity.

Execution abroad offers a separate test. Management expects United Kingdom drug supply and full launch later in the year, sees a potential Canadian approval, and plans further launches as national assessment processes are completed; progress against that sequence would demonstrate whether aficamten can become a geographically broader commercial franchise.

What management is planning

Management expectations, not completed milestones or guarantees. Selected verbatim excerpts; dates follow the transcript provider.

  1. We expect to launch MYQORZO in the U.K. in this quarter and complete enrollment in Cohort 1 of AMBER-HFpEF.

    Robert I. Blum ·

  2. And in early 2027, we expect to submit our application relating to the results of ACACIA-HCM in the EU and launch in additional countries in 2027 as well as share top line results from the adolescent cohort of CEDAR-HCM.

    Robert I. Blum ·

2 more statements are quoted under Upcoming events

5 · Peer comparison

How does Cytokinetics compare with its peers?

Short answer

Cytokinetics's score ranks 13th of 13 in the bounded comparison shown, against 12 same-model peers. These are company scores, not expected investment returns. The set lists named competitors first, then companies in the same data-provider industry classification closest in market value; that classification is the provider's, not our judgment of business similarity.

Cytokinetics is no longer simply a research-stage biotechnology company because MYQORZO is marketed and commercial spending is already prominent. Yet its economics still resemble a development-heavy business: revenue is uneven, losses are substantial, cash use is persistent and future profitability depends on a steep commercial expansion.

Its scientific distinction is a portfolio built around adjusting muscle contractility in different directions. Cardiac myosin inhibitors target hypercontractility, omecamtiv mecarbil is intended to address heart failure with severely reduced pumping function, and the skeletal-muscle program activates troponin rather than extending a conventional cardiology portfolio.

Peer set — price, market value and MoonshotScore
CompanyPriceMarket valueScore
Kiniksa Pharmaceuticals, Ltd. (KNSA) Same industry, near in market value$93.53 Nov 19, 2026$7.35B98 5-pillar Nov 18, 2026
Krystal Biotech, Inc. (KRYS) Same industry, near in market value$315.82 Nov 19, 2026$9.36B96 5-pillar Nov 18, 2026
Halozyme Therapeutics, Inc. (HALO) Named competitor$93.04 Nov 19, 2026$10.6B95 5-pillar Nov 18, 2026
Corcept Therapeutics Incorporated (CORT) Named competitor$67.79 Nov 18, 2026$7.42B91 5-pillar Nov 18, 2026
TG Therapeutics, Inc. (TGTX) Same industry, near in market value$64.88 Nov 19, 2026$9.81B90 5-pillar Nov 18, 2026
Protagonist Therapeutics, Inc. (PTGX) Same industry, near in market value$127.16 Nov 18, 2026$8.30B88 5-pillar Nov 18, 2026
Caris Life Sciences, Inc. (CAI) Same industry, near in market value$19.50 Nov 18, 2026$5.59B83 5-pillar Nov 18, 2026
Ligand Pharmaceuticals Incorporated (LGND) Same industry, near in market value$298.71 Nov 18, 2026$5.98B71 5-pillar Nov 18, 2026
Oruka Therapeutics, Inc. (ORKA) Same industry, near in market value$97.57 Nov 19, 2026$6.62B67 5-pillar Nov 18, 2026
Erasca, Inc. (ERAS) Same industry, near in market value$14.22 Nov 19, 2026$4.99B67 5-pillar Nov 18, 2026
Veradermics, Incorporated (MANE) Same industry, near in market value$124.39 Nov 19, 2026$5.25B66 5-pillar Nov 18, 2026
Belite Bio, Inc. (BLTE) Same industry, near in market value$156.23 Nov 18, 2026$6.35B64 5-pillar Nov 18, 2026
Cytokinetics (CYTK) — this page$51.46$7.17B12

Only 5-pillar scores are ranked together. Other models are not directly comparable. Price and score dates are shown separately; market-value dates are unavailable.

Screen more Healthcare stocks

The records behind this page

Analyst targets & estimates

What analysts have on file

Price target, low to high
$81.00 – $118.00
Consensus target
$107.14
Median target
$112.00

Consensus record · Captured .

Measured against a quoted price of $51.46 (as of Nov 19, 2026).

Insider activity

Form 4 records via FMP · Of the newest 100 records, those within the last 180 days, newest dated Nov 9, 2026

Transactions
100
Identified insiders
12
Purchases
0
Sales
28
Other transactions
72

Purchases and sales use the reported transaction category. Other transactions include awards, exercises, gifts, withholding and unclassified activity; an acquisition or disposition alone is not a purchase or sale. These records do not establish intent.

Who holds the shares?

Institutional ownership reported through 13F filings.

Reporting holders
491 Period end Sep 30, 2026
Previous quarter · holders
515 Prior to period end Sep 30, 2026
Holders in provider snapshotShares
Blackrock, INC.21,041,152
T. Rowe Price Investment Management, INC.18,912,704
Wellington Management Group Llp10,590,381
Polar Capital Holdings PLC9,635,314
State Street Corp7,143,229

Tracked investors

Which of the 16 named investors we follow held CYTK in their latest 13F filing, and what they did against the filing before it.

None of the 16 tracked investors reported CYTK in their latest 13F filing.

See all tracked investor portfolios

How to read these figures

These filings arrive after the quarter ends. Names appear as the provider lists them, not as a verified ranking, and without filing dates. Related managers can appear separately, so their shares are not added together. Holder snapshot as of Sep 30, 2026. Tracked investors: each fund's own latest 13F, so funds that have not filed the newest quarter yet show their previous one; weight is the share of the fund's reported 13F value.

What has been published about Cytokinetics (CYTK)?

Read these with our analysis →

What Investors Ask About Cytokinetics (CYTK) — Healthcare

The last 2 questions are answered from this page's own dated data, not from the research.

How does MYQORZO change Cytokinetics’ business model?

MYQORZO gives Cytokinetics a marketed therapy for symptomatic obstructive hypertrophic cardiomyopathy, adding product commercialization to collaboration economics and pipeline development. The financial statements have not yet settled into a stable product-led revenue pattern.

Why is aficamten’s international rollout staggered?

Management says launches depend on health-technology assessment processes within each country. The United Kingdom is expected to lead the next wave, with additional markets following as their local processes conclude.

Can Cytokinetics fund the MYQORZO and aficamten rollout from current liquidity?

Current cash and investments provide meaningful runway and exceed total debt when long-term investments are included. Persistent operating cash use, elevated launch spending and a cash balance below debt on the narrower liquidity basis mean financing risk has not disappeared.

What could Ulacamten add to Cytokinetics’ muscle platform?

Ulacamten extends the cardiac myosin inhibitor approach toward heart failure associated with excessive contractility rather than the marketed obstructive hypertrophic cardiomyopathy indication. It broadens the scientific opportunity while adding another clinical program to an already costly research portfolio.

What is the CYTK stock price today?

The last price recorded for Cytokinetics, Incorporated (CYTK), with its trading session and source, is listed under Price & valuation on this page. It is a provider snapshot, not a live exchange feed, so check a brokerage quote before you trade.

What is the CYTK price target?

The analyst consensus price target for Cytokinetics, Incorporated (CYTK), with its range and the date it was captured from FMP, is listed under Analyst targets & estimates on this page. Targets are analyst opinions and change often; they are not a Stock Expert AI forecast.

Research written by Codex (gpt-5.6-sol) on 2026-09-13. AI-authored analysis; source dates are listed under Sources. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief.

Sources: the source register lists the 78 figures on this page — 2 from SEC filings and earnings calls, 69 from Financial Modeling Prep (FMP), 3 with no recorded source, 3 computed by us, formula shown in the register and 1 from Stock Expert AI's own score and rank. Its rows (value as shown, as-of date, tier and source link) are in the Markdown version of this page.

Publication details and research sources
Published
Research standards
Methodology · Editorial policy · Corrections

Sources (as of 2026-09-13), by section of the research

  • Summary at the top of the page: Business description; Quarterly income statement (USD thousands); Operating cash flow by quarter (USD millions); Cash, investments and debt; Cash runway cross-check (ours); Management outlook — dated call excerpts
  • 1. What is Cytokinetics (CYTK), and what does it report?: Business description; Revenue by segment; Quarterly income statement (USD thousands); Annual revenue and net result (USD millions)
  • 2. What do the latest results show for Cytokinetics (CYTK)?: Quarterly income statement (USD thousands); Operating cash flow by quarter (USD millions); Reported versus estimated, last 8 quarters; Revenue by segment; Management outlook — dated call excerpts
  • 3. What are the financial strengths and risks for Cytokinetics (CYTK)?: Cash, investments and debt; Cash and investment components; Cash and short-term investments over time (USD millions); Cash runway cross-check (ours); Cash against market value; Operating cash flow by quarter (USD millions); Trailing twelve-month ratio set; Distress and quality screens; Analyst revenue and earnings estimates (average)
  • 4. What should you watch next at Cytokinetics (CYTK)?: Next earnings report; Quarterly income statement (USD thousands); Operating cash flow by quarter (USD millions); Revenue by segment; Management outlook — dated call excerpts
  • 5. How does Cytokinetics compare with its peers?: Business description; Quarterly income statement (USD thousands); Annual revenue and net result (USD millions); Operating cash flow by quarter (USD millions); Analyst revenue and earnings estimates (average)
  • FAQ: How does MYQORZO change Cytokinetics’ business model?: Business description; Revenue by segment; Quarterly income statement (USD thousands)
  • FAQ: Why is aficamten’s international rollout staggered?: Management outlook — dated call excerpts
  • FAQ: Can Cytokinetics fund the MYQORZO and aficamten rollout from current liquidity?: Cash, investments and debt; Cash and investment components; Cash runway cross-check (ours); Operating cash flow by quarter (USD millions); Cash against market value
  • FAQ: What could Ulacamten add to Cytokinetics’ muscle platform?: Business description; Annual revenue and net result (USD millions); Quarterly income statement (USD thousands)
Data Sources & Methodology
Figures come from Financial Modeling Prep (FMP). If FMP has no figure for a ticker, a price or fundamental may come from a Yahoo Finance fallback, or a price from an Alpaca fallback. SEC EDGAR is used only for filing links and company identity details (legal name, address), never for figures. AI analysis by Stock Expert AI proprietary algorithms. Technical indicators via industry-standard calculations. Last updated: .
Data Provenance
Sources: Financial Modeling Prep (FMP) — Primary · Yahoo Finance — Fallback · Alpaca — Tertiary
Last fetched:
Cache TTL: Quote 5min · Profile 7d · Financials 7d · Insider 48h
How we use AI: Numbers are pulled directly from FMP & Yahoo Finance — our AI writes the analysis, it never edits the figures.

ETFs that hold CYTK

Funds in our ETF coverage that list CYTK among the top 10 holdings on their fund page, largest weight first. Each weight is the fund's reported holding weight as of the date in its row.

ETFWeightHoldings as of
iShares Russell 2000 ETF (IWM)0.30%